Perrigo (PRGO) Declares $0.145 Quarterly Dividend; 0.6% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
Guggenheim Cuts PT On Perrigo (PRGO) By 30%
April 27, 2016 6:37 AM EDTGuggenheim analyst, Louise Chen, thinks Perrigo Co. (NYSE: PRGO) stock could experience downward pressure ahead of 1Q16 earnings but that earnings visibility going forward is likely to improve. Due to the executive departure, she cut her PT from $185 to $125 but maintained a Buy... More
S&P Downgrades Perrigo (PRGO) to 'BBB-'; Sees Weakness in High-Margin Business
April 26, 2016 12:14 PM EDTStandard & Poor's Ratings Services lowered all of its ratings on Perrigo Co. plc (NYSE: PRGO), including the corporate credit rating to 'BBB-' from 'BBB'. The outlook is stable. Reported debt outstanding as of Dec. 31, 2015 was about $6 billion.
"The downgrade reflects our expectation for weakness in Perrigo's high-margin generic pharmaceutical business, largely resulting from intensifying competition and lower pricing, and a further expected decline in the recently acquired European branded consumer business," said Standard & Poor's credit analyst Gerald Phelan. "As a result, we now forecast adjusted debt-to-EBITDA in the mid-3x area over... More



